home All News open_in_new Full Article

Antengene Announces IND Approval in China for Phase Ib/II Study of ATG

Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy  Morningstar


today 3 d. ago attach_file Politics

attach_file Economics
attach_file Economics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Events
attach_file Events
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Economics


ID: 2937225926
Add Watch Country

arrow_drop_down